VTRS
Viatris Inc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$18.48
+0.16%Year over year
Reported trailing growth
- Revenue
- +4.4%
- EBITDA
- +650.7%
- EBIT
- +96.6%
- EPS
- +87.6%
- Free cash flow
- +10.5%
- Operating cash flow
- +12.9%
Forward estimates
Based on analyst estimates
- Revenue
- +1.3%
- EBITDA
- +144.8%
- EPS
- +829.6%
Three-year CAGR
- Revenue
- -4.2%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -8.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026